asa guidelines for glp 1 drugs Glucagon-Like Peptide Receptor Agonists and Aspiration Risk Perioperative Use of GLP-1 Receptor
Description
Ultimately, these are decisions each employer must make based on its own employee population
These molecules are administered mainly by sub-cutaneous injection, and as such, remain in the peripheral bloodstream for a long period of time (with half-lives of days), but have little access to the intestinal vagal afferents
The breakdown shows 14.3% of patients have minimal retention, 44.3% show moderate amounts, and 41.4% have large quantities [3]
The severity of nausea can vary depending on the person
Other side effects can include dizziness, headache, and increased heart rate
